Preventative therapeutic approaches for hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Sarcomeric gene mutations are a primary cause of hypertrophic cardiomyopathy (HCM).
• Current HCM therapies alleviate symptoms but fail to prevent or reverse disease progression.
• Patient outcomes vary due to heterogeneous clinical manifestations and disease progression.

Purpose of the Study:

• To review the efficacy of current and potential hypertrophic cardiomyopathy therapeutics.
• To explore mutation-specific pathomechanisms in hypertrophic cardiomyopathy.
• To evaluate the potential of preventative therapeutic strategies for hypertrophic cardiomyopathy.

Main Methods:

• Systematic review of studies on hypertrophic cardiomyopathy therapeutics.
• Analysis of data from animal models of hypertrophic cardiomyopathy.
• Evaluation of human clinical trial results for hypertrophic cardiomyopathy treatments.

Main Results:

• Existing drug therapies for hypertrophic cardiomyopathy (HCM) offer symptomatic relief but do not alter disease trajectory.
• Pathophysiological changes in HCM, including calcium handling and sarcomeric disorganization, are linked to mutation-specific mechanisms.
• Therapeutic interventions may be more effective if implemented preventatively rather than correctively.

Conclusions:

• A preventative therapeutic approach may offer greater efficacy in managing hypertrophic cardiomyopathy (HCM).
• Understanding mutation-specific disease mechanisms is crucial for developing targeted and effective hypertrophic cardiomyopathy treatments.
• Personalized therapeutic strategies informed by genetic and mechanistic insights hold promise for improving hypertrophic cardiomyopathy outcomes.